Acute Myeloid Leukemia (AML) Therapeutic Market

Global Acute Myeloid Leukemia (AML) Therapeutic Market: Overview

As per Transparency Market Research, the global acute myeloid leukemia market (AML) therapeutics market will grow at a sturdy compound annual growth rate over the forecast period of 2020 to 2030 owing to growing incidence of AML.

Global Acute Myeloid Leukemia (AML) Therapeutic Market: Competitive Landscape

The vendor landscape of AML therapeutic market is slightly fragmented in terms of number of players and competitive owing to variety of growth strategies opted by them. Alliances and research and development hold a key place in the market. Top players include.                                                                                                                         

• Eli Lilly and Company
• Genzyme Corporation
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Celegene Corporation
• Cephalon, Inc.
• Eisai Inc.

Global Acute Myeloid Leukemia (AML) Therapeutics Market:  Key Trends and Drivers

• Advantages of biopharmaceuticals are being noted over conventional drugs and this is set to drive demand in the global acute myeloid leukemia therapeutics market. A strong pipeline of biopharmaceuticals currently marks the landscape, promising it a positive outlook in the future.
• Development of strong combination therapies is another growth factor lining the global acute myeloid leukemia therapeutics market. These are being used to treat a number of diseases. Previously, these were untreated. It is set to create novel and gainful avenues for players operating the AML playfield.

Global Acute Myeloid Leukemia (AML) Therapeutics Market:  Regional Analysis

North America is set to be at the forefront of growth in global AML therapeutics market owing to increasing research in the field and adoption of personalized medicine. Prevalence and incidence is leading to growth in the regional market over the forecast period.